Autologous cytokine-induced killer cell therapy in clinical trial phase I is safe in patients with primary hepatocellular carcinoma

Figure 1 Dynamic analysis of CIK cellular phenotypes by flow cytometry.

Figure 2 Phenotypic analysis of CD3⁺CD56⁺ cells in cultured cells by flow cytometry in various culture time.

Figure 3 Percentages of lymphocyte subsets in peripheral blood of HCC patients before and after CIK cell therapy.

Figure 4 Proportions of DCs in HCC patient peripheral blood before and after CIK cell transfusion.

Figure 5 Average HBV viral load in HCC patient serum before and after CIK cell transfusion.